Please login to the form below

Not currently logged in
Email:
Password:

New drugs breathe life into GSK's respiratory business

Revlar/Breo and Anoro offset ongoing Seretide decline with new sales growth
GSK

New drugs for asthma and chronic obstructive pulmonary disease (COPD) grew GlaxoSmithKline's respiratory sales in the second-quarter - for the first time since it lost patent protection for blockbuster Seretide/Advair.

The turnaround in the unit was a key factor in a return to form for GSK, with a second consecutive quarter of growth after a tricky couple of years which has seen generic competition erode around £2bn-worth of Seretide (salmeterol and fluticasone propionate) sales.

New asthma and COPD drugs such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide) added £243m ($319m) in the quarter, more than offsetting a 13% decline in Seretide sales to £900m although the respiratory unit as a whole had flat growth.

While US patent protection remains in place - likely until 2017 - there is still a sizeable drop in store for the Seretide/Advair franchise. GSK is hoping that approval of a new triple therapy - currently in late-stage trials - will help it cope with that eventuality.

Outgoing chief executive Sir Andrew Witty said the product's relative importance to the group is “dropping quickly" and - even if there is a big fall-off in the US - "it would hurt in the year [but is] no longer strategic in the sense that it once was".

A firmer respiratory business - coupled with strong growth for HIV drugs through the ViiV Healthcare joint venture which grew 44% to £865m - helped group sales rise 4% to £6.5bn overall. The weak pound - which has plummeted in the wake of the Brexit vote last month - also had a role to play.

GSK's vaccines unit added £960m in the second quarter - up 11% - with the rise driven largely by meningitis vaccine Bexsero, which saw sales more than double to £97m. Consumer health grew 7% to £1.69bn.

Growth was driven by all three divisions - pharmaceuticals, vaccines and consumer health - and put the company on course for earnings growth at the top end of expectations (up 11%-12%).

The results are a boost for Sir Andrew, who had promised a return to earnings growth in 2016 and told investors yesterday that the turnaround was a result of "growth in new product sales, continued cost control and delivery of restructuring and transaction benefits".

He also pointed to the strength of GSK's R&D pipeline, highlighting the new triple therapy for asthma, the recent EU approval for gene therapy Strimvelis, progress with its T-cell therapy for soft tissue sarcoma and first-in-class ICOS agonist 3359609, amongst others.

Article by
Phil Taylor

29th July 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
How to innovate and influence people in times of misinformation
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
Could femtech be the answer to the gender health gap?
Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...